<?xml version="1.0" encoding="UTF-8"?><rss version="2.0" xmlns:content="http://purl.org/rss/1.0/modules/content/"><channel><title>丰硕创投 | wechat-feeds</title><link>http://MzA3ODc3MDk2Nw.favicon.privacyhide.com/favicon.ico</link><description>聚焦医药投研</description><managingEditor> (hellodword)</managingEditor><pubDate>Wed, 16 Jun 2021 11:22:13 +0800</pubDate><image><url>http://MzA3ODc3MDk2Nw.favicon.privacyhide.com/favicon.ico</url><title>丰硕创投 | wechat-feeds</title><link>http://MzA3ODc3MDk2Nw.favicon.privacyhide.com/favicon.ico</link><width>64</width><height>64</height></image><item><title>时代渐变，快速跟随或成高危策略，以蛋白降解药物为例</title><link>https://mp.weixin.qq.com/s/nDTz9utGw2lk33RqYOhL6w</link><description></description><content:encoded><![CDATA[时代渐变，快速跟随或成高危策略，以蛋白降解药物为例]]></content:encoded><pubDate>Wed, 16 Jun 2021 10:23:47 +0800</pubDate></item><item><title>利用非天然氨基酸实现ADC 90%均一性的Ambrx Biopharma</title><link>https://mp.weixin.qq.com/s/eqh48qDojDbgncoIA8ZYGA</link><description></description><content:encoded><![CDATA[利用非天然氨基酸实现ADC 90%均一性的Ambrx Biopharma]]></content:encoded><pubDate>Tue, 15 Jun 2021 16:35:21 +0800</pubDate></item><item><title>PD-L1治疗非小细胞肺癌的国内市场会如何变动？</title><link>https://mp.weixin.qq.com/s/ghnUwik8Gpdb7Lt-4OsrwQ</link><description></description><content:encoded><![CDATA[PD-L1治疗非小细胞肺癌的国内市场会如何变动？]]></content:encoded><pubDate>Sat, 12 Jun 2021 22:07:52 +0800</pubDate></item><item><title>潜在的龙头，腾盛博药差异化的发展模式</title><link>https://mp.weixin.qq.com/s/ZmaLvhdbwmyiO1QdoV2P_w</link><description></description><content:encoded><![CDATA[潜在的龙头，腾盛博药差异化的发展模式]]></content:encoded><pubDate>Wed, 09 Jun 2021 10:44:23 +0800</pubDate></item><item><title>如何看信达引进ROS1/NTRK双靶点抑制剂Taletrectinib？</title><link>https://mp.weixin.qq.com/s/OfXXFrTAVuPgBAjTj7Rn1Q</link><description></description><content:encoded><![CDATA[如何看信达引进ROS1/NTRK双靶点抑制剂Taletrectinib？]]></content:encoded><pubDate>Mon, 07 Jun 2021 17:41:25 +0800</pubDate></item><item><title>AAV载体，在基因治疗时代大放异彩！</title><link>https://mp.weixin.qq.com/s/ydDm3rTCd9FyjTdCRAJRLw</link><description></description><content:encoded><![CDATA[AAV载体，在基因治疗时代大放异彩！]]></content:encoded><pubDate>Fri, 04 Jun 2021 15:44:21 +0800</pubDate></item><item><title>干货分享|如何做好医药行业研究？</title><link>https://mp.weixin.qq.com/s/Qd2GjPHM2ZtDmuOr4qNEwQ</link><description></description><content:encoded><![CDATA[干货分享|如何做好医药行业研究？]]></content:encoded><pubDate>Wed, 02 Jun 2021 10:13:33 +0800</pubDate></item><item><title>PI3Kδ抑制剂优于BTK抑制剂？！</title><link>https://mp.weixin.qq.com/s/I38whBv5fuqdVlNpXVXqOA</link><description></description><content:encoded><![CDATA[PI3Kδ抑制剂优于BTK抑制剂？！]]></content:encoded><pubDate>Tue, 01 Jun 2021 16:42:33 +0800</pubDate></item><item><title>盘点拿中国临床数据申报美国上市的企业</title><link>https://mp.weixin.qq.com/s/yuRVoqKc0c9mJeRC5UQhJQ</link><description></description><content:encoded><![CDATA[盘点拿中国临床数据申报美国上市的企业]]></content:encoded><pubDate>Wed, 26 May 2021 10:57:51 +0800</pubDate></item><item><title>AI公司Recursion：引领图像识别药物开发新潮流</title><link>https://mp.weixin.qq.com/s/NthuO5n1UyUnwbiVO3beCQ</link><description></description><content:encoded><![CDATA[AI公司Recursion：引领图像识别药物开发新潮流]]></content:encoded><pubDate>Tue, 25 May 2021 11:20:10 +0800</pubDate></item></channel></rss>